Nervous System News and Research

Latest Nervous System News and Research

Damon Runyon Cancer Research Foundation names 18 new Fellows

The Damon Runyon Cancer Research Foundation, a non-profit organization focused on supporting innovative early career researchers, named 18 new Damon Runyon Fellows at its fall Fellowship Award Committee review.

11 Jan 2012

Nicotine patch may help improve mild memory loss in older adults

Using a nicotine patch may help improve mild memory loss in older adults, according to a study published in the January 10, 2012, print issue of Neurology, the medical journal of the American Academy of Neurology.

10 Jan 2012

TCM therapy makes fertility treatments far more effective: Study

Traditional Chinese medicine has long been used to ease pain, treat disease, boost fertility, and prevent miscarriage. Known in the Western medical community by its acronym TCM, these traditional remedies include herbal preparations and acupuncture. Now Tel Aviv University researchers have discovered that a combination of TCM therapy and intrauterine insemination (IUI) is a winning solution for hopeful mommies who are having trouble conceiving.

10 Jan 2012

Modified probiotics could one day decrease risk of Listeria infection

Modified probiotics, the beneficial bacteria touted for their role in digestive health, could one day decrease the risk of Listeria infection in people with susceptible immune systems, according to Purdue University research.

10 Jan 2012

AAN, Wolters Kluwer Health announce launch of Neurology Today for the iPad

The American Academy of Neurology (AAN) and Wolters Kluwer Health today announced the launch of Neurology Today for the iPad, a digital app of the most widely read newspaper for neurologists.

10 Jan 2012

Enrollment complete in Diamyd Phase II study for type 1 diabetes

A total of 50 children aged four and older with a high risk of developing type 1 diabetes have been enrolled in a researcher-initiated Phase II study, DiAPREV-IT, with Diamyd Medical's diabetes vaccine Diamyd. The study is thus fully recruited.

9 Jan 2012

Georgia Bio announces 2012 Deals of the Year for pharma, biopharma and medical device companies

Georgia Bio announced its 2012 Deals of the Year for pharmaceutical, biopharmaceutical and medical device companies in four categories - public and private financings, fast growing companies, acquisitions and SBIR grants - reflecting a broad range of activity.

From Medtronic 7 Jan 2012

Study provides hope for stimulating remyelination in MS patients

Scientists at Joslin Diabetes Center, Harvard University, and the University of Cambridge have found that the age-related impairment of the body's ability to replace protective myelin sheaths, which normally surround nerve fibers and allow them to send signals properly, may be reversible, offering new hope that therapeutic strategies aimed at restoring efficient regeneration can be effective in the central nervous system throughout life.

7 Jan 2012

Age-associated decline of remyelination process may be reversible

New research highlights the possibility of reversing ageing in the central nervous system for multiple sclerosis (MS) patients. The study is published today, 06 January, in the journal Cell Stem Cell.

7 Jan 2012

Supernus secures $42M through two transactions

Supernus Pharmaceuticals, Inc. today announced that in December 2011 it closed two transactions through which it raised $42 million.

7 Jan 2012

Alnylam files CTA with the U.K. MHRA to initiate ALN-TTR02 Phase I trial in ATTR

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has filed a Clinical Trial Application (CTA) with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase I clinical trial with ALN-TTR02, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis.

7 Jan 2012

Positive topline results from Civitas' CVT-301 Phase 1 trial on PD

Civitas Therapeutics, Inc., a privately-held pharmaceutical company developing transformative therapeutics using the ARCUS(TM) respiratory delivery platform, announced today positive topline results from a Phase 1 clinical trial for CVT-301, an inhaled formulation of levodopa (L-dopa) for the rapid relief from motor fluctuations associated with Parkinson's disease.

7 Jan 2012

Scripps professor receives pair of notable grants to study kinesin

Sathyanaryanan Puthanveettil, an assistant professor on the Florida campus of The Scripps Research Institute, has been awarded a pair of notable grants to study a critical component of long-term memory formation.

6 Jan 2012

Study shows how Epstein-Barr virus triggers MS

A new study from researchers at Queen Mary, University of London shows how a particular virus tricks the immune system into triggering inflammation and nerve cell damage in the brain, which is known to cause MS.

6 Jan 2012

AstraZeneca plans to progress Targacept's AZD1446 as treatment for AD

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today announced that AstraZeneca has informed the company that it plans to progress the development of Targacept's product candidate AZD1446 as a treatment for Alzheimer's disease.

5 Jan 2012

RegeneRx's RGN-259 safe, well tolerated in patients with dry eye syndrome

RegeneRx Biopharmaceuticals, Inc. announced today that it has received the clinical study report for its recently completed Phase 2 clinical trial evaluating RGN-259 for the treatment of dry eye syndrome.

5 Jan 2012

Doctors may need to adjust seizure drug doses for people with HIV/AIDS: New AAN guideline

A new guideline issued by the American Academy of Neurology recommends doctors use caution when choosing seizure drugs for people with HIV/AIDS to avoid potential drug interactions.

5 Jan 2012

Bionomics, Ironwood partner to develop and commercialize novel anti-anxiety compound

Ironwood Pharmaceuticals, Inc. and Bionomics Limited today announced that they entered into a collaboration, research, and licensing agreement that will enable Ironwood to develop and commercialize Bionomics' investigational anti-anxiety compound BNC210 and other related compounds.

5 Jan 2012

Positive results from Alkermes ALKS 5461 phase 1/2 study on MDD

Alkermes plc today announced positive topline results from a phase 1/2 study of ALKS 5461, a novel drug compound for major depressive disorder (MDD) in patients who have an inadequate response to standard therapies for clinical depression.

5 Jan 2012

Researchers discover culprit that leads from heart failure to diabetes

Either heart failure or diabetes alone is bad enough, but oftentimes the two conditions seem to go together. Now, researchers reporting in the January Cell Metabolism appear to have found the culprit that leads from heart failure to diabetes and perhaps a novel way to break that metabolic vicious cycle.

4 Jan 2012